Patent ductus arteriosus (PDA) remains a prominent clinical challenge in the management of preterm infants. During fetal life, the ductus arteriosus diverts blood away from the underdeveloped lungs, ...
DENVER, April 22, 2022 – A randomized controlled trial evaluates if selective early treatment of patent ductus arteriosus reduces death or bronchopulmonary dysplasia at 36 weeks in extreme preterm ...
Char syndrome is a rare genetic condition that affects how a baby’s face, heart, and hands develop. It’s been found in only a few families worldwide. People with the condition have distinctive facial ...
The cyclooxygenase inhibitor ibuprofen may be used to treat patent ductus arteriosus (PDA) in preterm infants. Whether selective early treatment of large PDAs with ibuprofen would improve short-term ...
The multicentre, randomised, double-blind, placebo-controlled Baby-OSCAR trial. Participants were 653 extremely preterm infants with a large patent ductus arteriosus (diameter, ≥ 1.5 mm). In the first ...
Hosted on MSN
New guidance released to improve safety and outcomes of patent ductus arteriosus closure in premature infants
The Society for Cardiovascular Angiography & Interventions (SCAI) has published a new position statement that provides best-practice guidance for the treatment of patent ductus arteriosus (PDA) using ...
DEAR DR. ROACH: My husband is 80 years old and a survivor of liver cancer after receiving four years of immunotherapy. On a recent follow-up visit to his oncologist, the doctor told him that he has a ...
Merit Medical Systems initiates a study to evaluate the Bloom Micro Occluder System for treating patent ductus arteriosus in premature infants. Merit Medical Systems, Inc. has announced the enrollment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback